Trials / Recruiting
RecruitingNCT07461441
Efficacy and Durability of a Personalized Treat-and-extend Regimen of Faricimab for Treatment-naive Polypoidal Choroidal Vasculopathy
- Status
- Recruiting
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 50 (estimated)
- Sponsor
- Yeungnam University College of Medicine · Academic / Other
- Sex
- All
- Age
- 50 Years
- Healthy volunteers
- Not accepted
Summary
To evaluate the Efficacy of a personalized treat-and-extend regimen of faricimab for treatment-naive polypoidal choroidal vasculopathy
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Faricimab Injection [Vabysmo] | After applying topical anesthetic drops, intravitreal injections were delivered with a 30-gauge needle placed 3.5-4.0 mm posterior to the limbus. Patients were treated with faricimab (6 mg/0.05 ml). |
Timeline
- Start date
- 2026-03-01
- Primary completion
- 2028-11-30
- Completion
- 2028-11-30
- First posted
- 2026-03-10
- Last updated
- 2026-03-10
Locations
1 site across 1 country: South Korea
Source: ClinicalTrials.gov record NCT07461441. Inclusion in this directory is not an endorsement.